`571-272-7822
`
`Paper 25
`Entered: October 6, 2017
`
`
`
`
`
`APOTEX INC., APOTEX CORP.,
`ARGENTUM PHARMACEUTICALS LLC,
`ACTAVIS ELIZABETH LLC, TEVA PHARMACEUTICALS USA, INC.,
`SUN PHARMACEUTICAL INDUSTRIES, LTD.,
`SUN PHARMACEUTICAL INDUSTRIES, INC., and
`SUN PHARMA GLOBAL FZE,
`Petitioners,
`
`v.
`
`NOVARTIS AG.,
`Patent Owner.
`____________
`Case IPR2017-008541
`Patent US 9,187,405 B2
`_______________
`
`
`Before LORA M. GREEN, CHRISTOPHER M. KAISER,
`and ROBERT A. POLLOCK, Administrative Patent Judges.
`
`POLLOCK, Administrative Patent Judge.
`
`
`ORDER
`Conduct of the Proceeding
`Revising Due Dates 1–7
`37 C.F.R. § 42.5
`
`
`
`
`
`
`1Cases IPR2017-01550, IPR2017-01946, and IPR2017-01929 have been
`joined with this proceeding.
`
`
`
`IPR2017-00854
`Patent 9,187,405 B2
`
`In response to the October 5, 2017, correspondence from parties relating to
`Patent Owner’s desire to seek an extension of the schedule for IPR2017-00854 and
`consolidated cases in light of the Federal Circuit’s decision in Aqua Products, Inc.
`v. Matal, No. 2015-1177 (Fed. Cir. Oct. 4, 2017), we indicated that we would
`postpone Due Date 1 by four weeks to Friday, November 10, 2017, and adjust the
`remaining Due Dates accordingly to avoid inconveniencing either party. See Ex.
`3003.
`
`
`Accordingly, it is
`
`ORDERED that Due Dates 1–7 are revised as follows:
`
`DUE DATE 1 .................................................................. November 13, 2017
`Patent owner’s response to the petition
`Patent owner’s motion to amend the patent
`
`DUE DATE 2 ....................................................................... February 2, 2018
`Petitioner’s reply to patent owner’s response to petition
`Petitioner’s opposition to motion to amend
`
`DUE DATE 3 ........................................................................... March 2, 2018
`Patent owner’s reply to petitioner’s opposition to motion to amend
`
`DUE DATE 4 ......................................................................... March 23, 2018
`Motion for observation regarding cross-examination of reply witness
`Motion to exclude evidence
`Request for oral argument
`
` 2
`
`
`
`
`
`
`
`IPR2017-00854
`Patent 9,187,405 B2
`
`DUE DATE 5 ............................................................................. April 6, 2018
`Response to observation
`Opposition to motion to exclude
`
`DUE DATE 6 ........................................................................... April 13, 2018
`Reply to opposition to motion to exclude
`
`DUE DATE 7 ............................................................................ May 11, 2018
`Oral argument (if requested)
`
`
`
` 3
`
`
`
`
`
`
`
`IPR2017-00854
`Patent 9,187,405 B2
`
`FOR PETITIONER SUN PHARMA:
`Samuel Park
`WINSTON & STRAWN LLP
`spark@winston.com
`FOR PETITIONER APOTEX:
`Steven W. Parmelee
`Michael T. Rosato
`Jad A. Mills
`WILSON SONSINI GOODRICH & ROSATI
`sparmelee@wsgr.com
`mrosato@wsgr.com jmills@wsgr.com
`FOR PETITIONER ARGENTUM:
`Teresa Stanek Rea
`Deborah H. Yellin
`Shannon M. Lentz
`CROWELL & MORING LLP
`TRea@Crowell.com
`DYellin@crowell.com
`SLentz@Crowell.com
`Tyler C. Liu
`ARGENTUM PHARMACEUTICALS, LLC
`TLiu@agpharm.com
`FOR PETITIONER TEVA:
`Amanda Hollis
`Eugene Goryunov
`KIRKLAND & ELLIS LLP
`amanda.hollis@kirkland.com
`egoryunov@kirkland.com
`
`FOR PATENT OWNER:
`Jane M. Love
`GIBSON, DUNN & CRUTCHER LLP
`jlove@gibsondunn.com
`
` 4
`
`
`
`
`
`